Eli Lilly and Company Capital Reinvestment Ratio
Eli Lilly and Company capital reinvestment ratio. Eli Lilly and Company (LILY34) has a Capital Reinvestment Ratio of 0.47x as of March 2026, meaning it reinvests 0% of its operating cash flow (R$5.33 Billion) in capital expenditures (R$2.53 Billion). See Eli Lilly and Company free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Eli Lilly and Company (2014–2025)
Capital reinvestment ratio of Eli Lilly and Company from 2014 to 2025. This chart tracks Eli Lilly and Company's Capital Reinvestment Ratio across 12 annual periods. See Eli Lilly and Company (LILY34) flexibility index to measure the company's free cash flow as a share of total liabilities.
Eli Lilly and Company Capital Reinvestment Ratio by Year (2014–2025)
Eli Lilly and Company capital reinvestment ratio by year from 2014 to 2025. For the full cash flow conversion analysis, see LILY34 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (BRL) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | R$16.81 Billion | R$10.85 Billion | ▼ -32.3% |
| 2024 | 0.95x | R$8.82 Billion | R$8.40 Billion | ▼ -7.4% |
| 2023 | 1.03x | R$5.71 Billion | R$5.88 Billion | ▲ +293.1% |
| 2022 | 0.26x | R$7.08 Billion | R$1.85 Billion | ▲ +45.1% |
| 2021 | 0.18x | R$7.26 Billion | R$1.31 Billion | ▼ -42.2% |
| 2020 | 0.31x | R$6.50 Billion | R$2.03 Billion | ▲ +11.6% |
| 2019 | 0.28x | R$4.84 Billion | R$1.35 Billion | ▼ -48.8% |
| 2018 | 0.55x | R$5.52 Billion | R$3.02 Billion | ▲ +41.8% |
| 2017 | 0.39x | R$5.62 Billion | R$2.16 Billion | ▲ +71.2% |
| 2016 | 0.23x | R$4.85 Billion | R$1.09 Billion | ▼ -37.4% |
| 2015 | 0.36x | R$2.96 Billion | R$1.07 Billion | ▲ +37.9% |
| 2014 | 0.26x | R$4.46 Billion | R$1.16 Billion | — |